{
    "title": "Sanofi's Dupixent wins U.S. approval for bigger use",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10838519/Sanofis-Dupixent-wins-U-S-approval-bigger-use.html",
    "date": "2022-05-20",
    "keywords": [
        "dupixent",
        "drug",
        "friday",
        "eoe",
        "sanofi",
        "sanofis",
        "regeneron",
        "dermatitis",
        "revenue",
        "approval",
        "bestselling",
        "injection",
        "inflammation",
        "esophagus",
        "food",
        "administration",
        "esophagitis",
        "filing",
        "review",
        "agency",
        "company",
        "end",
        "condition",
        "change",
        "treatment",
        "cause",
        "antiinflammation",
        "range",
        "atopic",
        "eczema",
        "course",
        "march",
        "target",
        "use",
        "disease",
        "copd",
        "lung",
        "trial",
        "year",
        "group",
        "product",
        "growth",
        "blockbuster",
        "rebound",
        "demand",
        "quarter",
        "analyst",
        "consensus",
        "asthma",
        "burger",
        "reporting",
        "maju",
        "samuel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}